Podcast: Breast Tomosynthesis - One Practice's Experience
In this podcast, Stephen Rose, MD, president and CEO of Houston Breast Imaging and a principal investigator of the 3-D tomosynthesis clinical trials in 2010, discusses the benefits of the new technology and what his practice learned when implementing the screening program.
[[{"type":"media","view_mode":"media_crop","fid":"11554","attributes":{"alt":"Stephen Rose","class":"media-image media-image-left","id":"media_crop_8501769795264","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"218","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: left;","title":" ","typeof":"foaf:Image"}}]]In February 2011, the FDA approved the first X-ray mammography system that provides 3-D images for breast cancer screening and diagnosis, Hologic’s Selenia Dimensions. The 3-D tomosynthesis is being offered in fewer than two dozen locations in the U.S., and among them is Houston Breast Imaging in Texas.
In this podcast, Stephen Rose, MD, president and CEO of Houston Breast Imaging and a principal investigator of the 3-D tomosynthesis clinical trials in 2010, discusses the benefits of the new technology and what his practice learned when implementing the screening program. .
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
